Future of Immunotherapy in Ovarian Cancer to Include Combinations – OncLive
OncLive |
Future of Immunotherapy in Ovarian Cancer to Include Combinations
OncLive Prior studies of single-agent immunotherapy with checkpoint inhibitors have generally failed to show benefit in patients with ovarian cancer. This has not deterred investigators though, as there are currently 5 phase III clinical trials evaluating … |
